Page 659«..1020..658659660661..670680..»

A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic | Scientific Reports – Nature.com

Posted: August 31, 2021 at 2:04 am

Simon-Loriere, E. & Holmes, E. C. Why do RNA viruses recombine?. Nat. Rev. Microbiol. 9, 617626. https://doi.org/10.1038/nrmicro2614 (2011).

CAS Article PubMed PubMed Central Google Scholar

Dhama, K. et al. Coronavirus disease 2019-COVID-19. Clin. Microbiol. Rev. 33, e0002820. https://doi.org/10.1128/cmr.00028-20 (2020).

CAS Article Google Scholar

Cheng, V. C., Lau, S. K., Woo, P. C. & Yuen, K. Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 20, 660694. https://doi.org/10.1128/cmr.00023-07 (2007).

CAS Article PubMed PubMed Central Google Scholar

Neches, R. Y., McGee, M. D. & Kyrpides, N. C. Recombination should not be an afterthought. Nat. Rev. Microbiol. 18, 606. https://doi.org/10.1038/s41579-020-00451-1 (2020).

CAS Article PubMed Google Scholar

Paraskevis, D. et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect. Genet. Evol. 79, 104212. https://doi.org/10.1016/j.meegid.2020.104212 (2020).

CAS Article PubMed PubMed Central Google Scholar

Wu, A. et al. Mutations, Recombination and Insertion in the evolution of 2019-nCoV. bioRxiv https://doi.org/10.1101/2020.02.29.971101 (2020).

Article PubMed PubMed Central Google Scholar

Vijgen, L. et al. Complete genomic sequence of human coronavirus OC43: Molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 79, 15951604. https://doi.org/10.1128/jvi.79.3.1595-1604.2005 (2005).

CAS Article PubMed PubMed Central Google Scholar

Zhang, Y. et al. Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural recombination. J. Infect. 70, 641650. https://doi.org/10.1016/j.jinf.2014.12.005 (2015).

Article PubMed Google Scholar

Zhang, Z., Shen, L. & Gu, X. Evolutionary dynamics of MERS-CoV: Potential recombination, positive selection and transmission. Sci. Rep. 6, 25049. https://doi.org/10.1038/srep25049 (2016).

ADS CAS Article PubMed PubMed Central Google Scholar

Zhang, X. W., Yap, Y. L. & Danchin, A. Testing the hypothesis of a recombinant origin of the SARS-associated coronavirus. Arch. Virol. 150, 120. https://doi.org/10.1007/s00705-004-0413-9 (2005).

CAS Article PubMed Google Scholar

Liu, P. et al. Prevalence and genetic diversity analysis of human coronaviruses among cross-border children. Virol. J. 14, 230. https://doi.org/10.1186/s12985-017-0896-0 (2017).

CAS Article PubMed PubMed Central Google Scholar

Kin, N., Miszczak, F., Lin, W., Gouilh, M. A. & Vabret, A. Genomic analysis of 15 Human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes. Viruses 7, 23582377. https://doi.org/10.3390/v7052358 (2015).

CAS Article PubMed PubMed Central Google Scholar

Lau, S. K. et al. Severe acute respiratory syndrome (SARS) coronavirus ORF8 protein is acquired from SARS-related coronavirus from greater horseshoe bats through recombination. J. Virol. 89, 1053210547. https://doi.org/10.1128/jvi.01048-15 (2015).

CAS Article PubMed PubMed Central Google Scholar

Lau, S. K. et al. Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination. J. Virol. 85, 1132511337. https://doi.org/10.1128/jvi.05512-11 (2011).

CAS Article PubMed PubMed Central Google Scholar

Dominguez, S. R. et al. Genomic analysis of 16 Colorado human NL63 coronaviruses identifies a new genotype, high sequence diversity in the N-terminal domain of the spike gene and evidence of recombination. J. Gen. Virol. 93, 23872398. https://doi.org/10.1099/vir.0.044628-0 (2012).

CAS Article PubMed PubMed Central Google Scholar

Pyrc, K. et al. Mosaic structure of human coronavirus NL63, one thousand years of evolution. J. Mol. Biol. 364, 964973. https://doi.org/10.1016/j.jmb.2006.09.074 (2006).

CAS Article PubMed PubMed Central Google Scholar

Woo, P. C. et al. Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1. J. Virol. 80, 71367145. https://doi.org/10.1128/jvi.00509-06 (2006).

CAS Article PubMed PubMed Central Google Scholar

Sabir, J. S. et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351, 8184. https://doi.org/10.1126/science.aac8608 (2016).

ADS CAS Article PubMed Google Scholar

Wang, Y. et al. Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis. MBio 6, e01280-01215. https://doi.org/10.1128/mBio.01280-15 (2015).

CAS Article Google Scholar

Eden, J. S., Tanaka, M. M., Boni, M. F., Rawlinson, W. D. & White, P. A. Recombination within the pandemic norovirus GII.4 lineage. J. Virol. 87, 62706282. https://doi.org/10.1128/jvi.03464-12 (2013).

CAS Article PubMed PubMed Central Google Scholar

Dearlove, B. et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc. Natl. Acad. Sci. USA 117, 2365223662. https://doi.org/10.1073/pnas.2008281117 (2020).

Article PubMed PubMed Central Google Scholar

Montoya, V. et al. Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing. Infect. Genet. Evol. 43, 329337. https://doi.org/10.1016/j.meegid.2016.06.015 (2016).

CAS Article PubMed Google Scholar

Prez-Losada, M., Arenas, M., Galn, J. C., Palero, F. & Gonzlez-Candelas, F. Recombination in viruses: Mechanisms, methods of study, and evolutionary consequences. Infect. Genet. Evol. 30, 296307. https://doi.org/10.1016/j.meegid.2014.12.022 (2015).

CAS Article PubMed Google Scholar

Hamre, D. & Procknow, J. J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190193. https://doi.org/10.3181/00379727-121-30734 (1966).

CAS Article PubMed Google Scholar

https://www.newscientist.com/article/2268379-two-coronavirus-variants-have-merged-heres-what-you-need-to-know/, cited Feb 20 2021.

Eguia, R. T. et al. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 17, e1009453. https://doi.org/10.1371/journal.ppat.1009453 (2021).

CAS Article PubMed PubMed Central Google Scholar

McIntosh, K., Becker, W. B. & Chanock, R. M. Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease. Proc. Natl. Acad. Sci. USA 58, 22682273. https://doi.org/10.1073/pnas.58.6.2268 (1967).

ADS CAS Article PubMed PubMed Central Google Scholar

McIntosh, K. et al. Seroepidemiologic studies of coronavirus infection in adults and children. Am. J. Epidemiol. 91, 585592. https://doi.org/10.1093/oxfordjournals.aje.a121171 (1970).

CAS Article PubMed Google Scholar

Kahn, J. S. & McIntosh, K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24, S223-227. https://doi.org/10.1097/01.inf.0000188166.17324.60 (2005) (discussion S226).

Article PubMed Google Scholar

Chen, R. & Vasilakis, N. Denguequo tu et quo vadis?. Viruses 3, 15621608. https://doi.org/10.3390/v3091562 (2011).

Article PubMed PubMed Central Google Scholar

https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563. Accessed 31 Dec 2020.

CDC. SARS-CoV-2 Variant Classifications and Definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.

Didelot, X., Gardy, J. & Colijn, C. Bayesian inference of infectious disease transmission from whole-genome sequence data. Mol. Biol. Evol. 31, 18691879. https://doi.org/10.1093/molbev/msu121 (2014).

CAS Article PubMed PubMed Central Google Scholar

Pickett, B. E. et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res. 40, D593-598. https://doi.org/10.1093/nar/gkr859 (2012).

CAS Article PubMed Google Scholar

Katoh, K. & Standley, D. M. MAFFT: iterative refinement and additional methods. Methods Mol. Biol. 1079, 131146. https://doi.org/10.1007/978-1-62703-646-7_8 (2014).

Article PubMed Google Scholar

Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. MEGA6: Molecular evolutionary genetics analysis version 6.0. Mol. Biol. Evol. 30, 27252729. https://doi.org/10.1093/molbev/mst197 (2013).

CAS Article PubMed PubMed Central Google Scholar

https://www.gisaid.org/. Accessed 9 Jan 2021.

Capella-Gutirrez, S., Silla-Martnez, J. M. & Gabaldn, T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. Bioinformatics 25, 19721973. https://doi.org/10.1093/bioinformatics/btp348 (2009).

CAS Article PubMed PubMed Central Google Scholar

Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B. RDP4: Detection and analysis of recombination patterns in virus genomes. Virus Evol 1, vev003. https://doi.org/10.1093/ve/vev003 (2015).

Article PubMed PubMed Central Google Scholar

Martin, D. & Rybicki, E. RDP: Detection of recombination amongst aligned sequences. Bioinformatics 16, 562563. https://doi.org/10.1093/bioinformatics/16.6.562 (2000).

CAS Article PubMed Google Scholar

Martin, D. P., Posada, D., Crandall, K. A. & Williamson, C. A modified bootscan algorithm for automated identification of recombinant sequences and recombination breakpoints. AIDS Res. Hum. Retroviruses 21, 98102. https://doi.org/10.1089/aid.2005.21.98 (2005).

CAS Article PubMed Google Scholar

Smith, J. M. Analyzing the mosaic structure of genes. J. Mol. Evol. 34, 126129. https://doi.org/10.1007/bf00182389 (1992).

ADS CAS Article PubMed Google Scholar

Posada, D. & Crandall, K. A. Evaluation of methods for detecting recombination from DNA sequences: computer simulations. Proc. Natl. Acad. Sci. USA 98, 1375713762. https://doi.org/10.1073/pnas.241370698 (2001).

ADS CAS Article PubMed PubMed Central Google Scholar

Lam, H. M., Ratmann, O. & Boni, M. F. Improved algorithmic complexity for the 3SEQ recombination detection algorithm. Mol. Biol. Evol. 35, 247251. https://doi.org/10.1093/molbev/msx263 (2018).

CAS Article PubMed Google Scholar

Padidam, M., Sawyer, S. & Fauquet, C. M. Possible emergence of new geminiviruses by frequent recombination. Virology 265, 218225. https://doi.org/10.1006/viro.1999.0056 (1999).

CAS Article PubMed Google Scholar

Gibbs, M. J., Armstrong, J. S. & Gibbs, A. J. Sister-scanning: a Monte Carlo procedure for assessing signals in recombinant sequences. Bioinformatics 16, 573582. https://doi.org/10.1093/bioinformatics/16.7.573 (2000).

CAS Article PubMed Google Scholar

Weiller, G. F. Phylogenetic profiles: A graphical method for detecting genetic recombinations in homologous sequences. Mol. Biol. Evol. 15, 326335. https://doi.org/10.1093/oxfordjournals.molbev.a025929 (1998).

CAS Article PubMed Google Scholar

Lemey, P., Lott, M., Martin, D. P. & Moulton, V. Identifying recombinants in human and primate immunodeficiency virus sequence alignments using quartet scanning. BMC Bioinformatics 10, 126. https://doi.org/10.1186/1471-2105-10-126 (2009).

CAS Article PubMed PubMed Central Google Scholar

Darriba, D., Taboada, G. L., Doallo, R. & Posada, D. jModelTest 2: More models, new heuristics and parallel computing. Nat. Methods 9, 772. https://doi.org/10.1038/nmeth.2109 (2012).

CAS Article PubMed PubMed Central Google Scholar

Guindon, S. & Gascuel, O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52, 696704. https://doi.org/10.1080/10635150390235520 (2003).

Article PubMed Google Scholar

Rambaut, A., Lam, T. T., MaxCarvalho, L. & Pybus, O. G. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol. 2, vew007. https://doi.org/10.1093/ve/vew007 (2016).

Article PubMed PubMed Central Google Scholar

https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf. Accessed 31 Dec 2020.

Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol. 4, vey016. https://doi.org/10.1093/ve/vey016 (2018).

Read more:
A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic | Scientific Reports - Nature.com

Posted in Molecular Genetics | Comments Off on A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic | Scientific Reports – Nature.com

New faculty bring expertise in abstract algebra, insulin chemistry and more to USC > News > USC Dornsife – USC Dornsife College of Letters, Arts…

Posted: August 31, 2021 at 2:04 am

Meet the life sciences, physical sciences and mathematics faculty joining USC Dornsife this fall. [3 min read]

Scholars in the natural sciences and mathematics join USC Dornsife this fall to teach and conduct research. (Composite: Dennis Lan.)

Four new faculty members join the USC Dornsife College of Letters, Arts and Sciences life sciences, physical sciences and mathematics divisions for the fall 2021 semester. They recently shared their academic work and personal interests.

Michael Campbell | Assistant Professor of Biological Sciences

Academic focus:Current genetic and paleontological evidence tells us that anatomically modern humans evolved in Africa about 300,000 years ago and then migrated around the globe within the last 100,000 years. Demographic events along with natural selection, have shaped the patterns of genetic diversity in contemporary populations.

One of the grand challenges now that weve sequenced the human genome is to better understand the interplay between evolutionary history, genomic variation and the development of human traits. My research explores the use of statistical, computational and field-based approaches to identify polymorphisms places where DNA on one chromosome differs from the matching spot on another chromosome favored by evolution but that contribute to variable traits, including disease susceptibility, in diverse human populations.

What do you like to do in your spare time? Although I dont have a lot of spare time these days, whenever it arises, I like to play trivia games. Im a die-hardJeopardy!fan.

If you could invite one person to dinner, living or dead, who would you select? What would be on the menu? While technically not one person, I would invite former President Barack Obama and former First Lady Michelle Obama. (I consider them an inseparable marital unit.) This would be a very informal dinner with barbecue chicken and steak on the menu.

What food or condiments will we always find in your kitchen? Avocados, bread and ketchup (not necessarily eaten together).

Derrick Morton | Assistant Professor of Biological Sciences

Academic focus:My research focuses on incorporating genetic approaches to understand key pathways that control an organisms growth and development, and how alterations in gene expression contribute to neurological disease.

What inspires you? The greats of the civil rights movement inspire me. I stand on the shoulders of giants, and their collective sacrifices are a constant reminder of what it took for me to achieve. There are no words to adequately express my gratitude.

If you could invite one person to dinner, living or dead, who would you select? What would be on the menu? This is a tough one. I would likely choose to have Barack Obama over for dinner for the obvious reasons hes the former President of the U.S. and seems to be a pretty cool guy. I am a southern guy; my dinner menu would likely include a southern dish with dessert old fashioned banana pudding!

What food or condiments will we always find in your kitchen? Chicken, seafood (ingredients for a seafood boil: snow crab legs, shrimp, potatoes, sausage and corn my husband is from Florida), unsweetened tea (I know, not very southern of me) and wine.

Morton is teachingBISC 502a: Molecular Genetics and Biochemistrythis fall.

Cris Negron| Assistant Professor of Mathematics

In my work, I focus on the intersections between abstract algebra and mathematical physics.

What do you like to do in your spare time?Skateboard.

Where is your favorite place to travel?Oaxaca, Mexico.

Favorite book youve read lately?Noopimingby Leanne Betasamosake Simpson

Negron is teaching the graduate courseMATH 510a: Algebrathis fall.

Kate White| Assistant Professor (Research) ofChemistry

Academic focus:My labs goal is to help bridge the gap between structural biology how biological molecules are built, function and interact and physiology by pioneering new experimental and computational tools for multi-scale structural biology, from the atomic scale up to the level of cells. Our lab is investigating insulin chemistry and multiscale organization of pancreatic beta cells and applying new approaches to modeling entire cells.

If you could invite one person to dinner, living or dead, who would you select? What would be on the menu?Elon Musk. I wouldnt care what we ate, just interested in the discussion.

Where is your favorite place to travel?Yosemite.

What inspires you? The unknown.

Learn about other faculty joining USC Dornsife this fall here >>

Read the original here:
New faculty bring expertise in abstract algebra, insulin chemistry and more to USC > News > USC Dornsife - USC Dornsife College of Letters, Arts...

Posted in Molecular Genetics | Comments Off on New faculty bring expertise in abstract algebra, insulin chemistry and more to USC > News > USC Dornsife – USC Dornsife College of Letters, Arts…

What I Learnt From The Happiest Person In The World – YourTango

Posted: August 31, 2021 at 2:04 am

Beinghappy is not a competition.Or at least, I thought it wasnt. But Google tells me there is a man who has won this race and been named the happiest person in the world. In fact, there has been scientific research done to prove this claim.

RELATED:10 Items To Stop Counting If You Want To Be Truly Happy

The scans showed that when meditating on compassion, Ricards brain produces a level of gamma waves those linked to consciousness, attention, learning, and memory never reported before in the neuroscience literature, said Richard Davidson, the neuroscientist from the University of Wisconsin.

His name is Matthieu Ricard. He is 75 years old and lives in Nepal in a Buddhist monastery. Prior to becoming a monk, he was a scientist and received his Ph.D. in molecular genetics.

So, how did he do it? Well, Ricard himself has said that anyone can be the happiest person in the world if they look for happiness in the right place. The problem is that we tend not to.

As a Buddhist monk, he meditates a lot. According to him, by sitting and cultivating compassion, our mind will change, our brain will change, and then our lives will change. All by dedicating a few minutes a day, every day. Ricard also talks about spending a few minutes thinking happy thoughts every morning.

Can simply meditatingmake someone a happier person? I decided to try this for myself.

I made myself meditate for ten minutes every day for a month. Now, I am sure Matthieu Ricard meditates way more than this but since I am a beginner, this was a good place for me to start.

The first day I looked foraguided meditation videoon YouTube and sat alone in a room with my legs crossed and eyes closed. I wont lie. It was difficult and I dont think I did a very good job. I kept getting distracted. But by the end of the ten minutes, there were tears on my cheeks!

What? I didnt understand. I wasnt sad but I was crying. Why? A quick online search told me it was quite common for people to cry after a meditation session. I also felt much lighter. Earlier that day I was stressed about an upcoming project but after that meditation session, I was calm. I knew I had enough time to complete that project and I didnt have anything to worry about.

I continued doing this every day for the whole month. I cried again a few more times but every time I meditated, I felt so good. Was this the happiness Ricard talks about? Maybe.

Now, of course, Id feel distracted sometimes. Those 10 minutes werent flawless by any means. Id get bored or feel like I wanted to do something else, which is normal because just sitting in silence isnt exactly the norm for most people.

But I didnt go into this thinking I was going to come out on the other end feeling like a much happier version of myself. I dont even know what that means or what that would look like. I went into it with an open mind, curious to how I would feel being in a state of mind where Im devoting 10 minutes straight, every day, wishing love and compassion upon others and upon myself.

And quite frankly, it felt really good.

However, those positive emotions didnt really last for very long once I was done with the 10 minutes. I believe for any lasting change, Ill have to meditate a lot longer than ten minutes a day for a month.

RELATED:What Buddhists Believe & 20 Buddha Quotes On Healthy Living

I highly recommend everyone to try meditation at least once. But not because meditation holds the secret key to happiness. In fact, I learned that meditation isnt where happiness is the happiness already exists within you, meditation helps dig it out.

In fact, happiness looks different for different people. Here are some popular personalities describing what happiness means to them.

Paulo Coelho wrote in The Alchemist, If you can concentrate always on the present, youll be a happy man.

Join now for YourTango's trending articles, top expert advice and personal horoscopes delivered straight to your inbox each morning.

Helen Keller said, A happy life consists not in the absence, but in the mastery of hardships.

I hope everybody could get rich and famous and will have everything they ever dreamed of so they will know that is not the answer to happiness, said Jim Carrey.

Jane Austen wrote, A large income is the best recipe for happiness I ever heard of.

Meditation helps us understand what happiness means to each of us. For some its getting 10k views on an article, for some, its eating ice cream on a hot summer day.

Ricard says that the feelings of love and happiness are often fleeting because once they occur, were quick to move on to the next thought. So rather than doing that, one should concentrate on not letting your mind get distracted and keep focused on the positive emotions for an extended period of time.

After following Ricards advice for 30 days, I learned that our thoughts hold way more power over us than we realize. And just by changing the way we think, we can truly change our lives.

RELATED:What Is Buddhism? + 6 Meditations To Find Your Inner Zen

Vidhipssa Mohan is a writer who focuses on love and mental health. She has been featured in Medium, Notion Press, The Startup, and more. Follow her on Twitter.

This article was originally published at Medium. Reprinted with permission from the author.

See the original post here:
What I Learnt From The Happiest Person In The World - YourTango

Posted in Molecular Genetics | Comments Off on What I Learnt From The Happiest Person In The World – YourTango

CDI Director Perlin Named to Modern Healthcare’s Class of Top 25 Innovators – Markets Insider

Posted: August 31, 2021 at 2:04 am

NUTLEY, N.J., Aug. 24, 2021 /PRNewswire/ --Hackensack Meridian Healthis proud to announce that David S. Perlin, Ph.D., chief scientific officer and senior vice president of the Hackensack Meridian Center for Discovery and Innovation (CDI), has been recognized by Modern Healthcare as one of this year's Top 25 Innovators.

The complete ranking is featured in the August 16 issue of MH magazine, and profiles of the honorees are available at ModernHealthcare.com/awards/top-25-innovators-2021.

The nomination of Perlin focused on the CDI's achievements during the COVID-19 era, which included testing, tracking, and therapeutic breakthroughs to benefit patients across Hackensack Meridian Health, New Jersey's largest and most comprehensive health network.

"Dr. David Perlin and the CDI have been a crucial resource for our health network during the pandemic," said Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. "Dr. Perlin's clear-eyed vision, and his experience with previous infectious disease outbreaks, has saved lives. This latest award is just further validation of his leadership."

"This award is a great honor," said Dr. Perlin. "The CDI aims to improve lives through real-time application of science, and I believe this distinction shows that our whole team here is making that difference, by responding to unmet needs."

The award nomination focused on the CDI's COVID-19 response, which played a critical role by impacting clinical care through development of novel diagnostics, improved antiviral therapy, and support of numerous clinical trial regimens.

The achievements include:

CDI scientists are also studying the biology of the virus, host factors that impact disease progression, and discovery and development of novel drug candidates.

"Dr. Perlin and his colleagues at the CDI have brought a new dimension of science to our research programs at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, the chief research officer and president of the Northern Region of Hackensack Meridian Health. "The future for our patients is bright."

Dr. Perlin joined the Center for Discovery and Innovation in January 2019. In May 2020, he received a $33.3 million grant from the National Institutes of Health to develop new antibiotics to overcome deadly bacteria in hospitals that have become resistant to current treatments.

One of Perlin's chief areas of expertise is drug resistant fungal pathogens, which includes Candida auris, a deadly fungal infection that is currently one of the most high-profile emerging threats in health care. Dr. Perlin and his colleagues developed one of the first comprehensive rapid diagnostic test for this pathogen and helped elucidate the principal mechanisms of drug resistance. His group has worked closely with the CDC on this epidemic in New York and New Jersey, and other global health departments.

Over a period of about 30 years, Dr. Perlin has been at the forefront of scientific research into combatting high-threat bacterial, viral and fungal pathogens. He helped develop a number of novel therapeutics and diagnostics, some of which are now commercial products. He also developed a wide range of domestic and global programs addressing both hospital- and community-associated drug resistance. His team of researchers has developed molecular diagnostic products for the CDC and local hospitals for multidrug resistant outbreak pathogens including drug-resistance determinants. He has worked with numerous device manufacturers and pharmaceutical companies, as well as with the FDA and EMA. He also serves as an advisory board member to numerous pharmaceutical, biotech and diagnostic companies for development of novel therapeutics and diagnostics targeting drug-resistant pathogens.

Prior to joining the Center for Discovery and Innovation, Dr. Perlin spent nearly 20 years as executive director of the Rutgers New Jersey Medical School's Public Health Research Institute (PHRI), an 80-year-old specialized center for global infectious diseases. He was also director of the Rutgers Regional Biocontainment Laboratory (RBL), one of 13 NIH-designated national centers for high-threat pathogen research, and was also a professor of microbiology, biochemistry and molecular genetics at the school. At PHRI, he oversaw programs to address multidrug resistant bacterial and fungal pathogens, both locally and abroad. He has published more than 300 papers and book chapters and co-authored two books.Dr. Perlin's awards include being named a Fellow of the New York Academy of Sciences and a Fellow of the American Academy of Microbiology.

This year's Top 25 Innovators for Modern Healthcare championed solutions to reshape the industry in big and small ways, pushing boundaries to help solve healthcare's greatest challenges.

"There's never been a more urgent time for the industry to experiment with innovations that can reshape how care is delivered. The members of this year's class of Top 25 Innovators have introduced ideas that engage consumers in new ways, lower healthcare costs and take unique approaches to managing population health. The honorees were selected for their work in one of four areas: consumerism, cost reduction, population health and quality/safety. They were selected from nearly 200 nominations. We congratulate this class of honorees and look forward to following their careers," said Aurora Aguilar, editor of Modern Healthcare.

ABOUT HACKENSACK MERIDIAN HEALTHHackensack MeridianHealthis a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack MeridianHealthcomprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Johnson Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness center, rehabilitation centers, urgent care centers and physician practice locations. Hackensack MeridianHealthhas more than 36,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network's notable distinctions include havingmore top-ranked hospitals than anyone in New Jersey, as recognized byU.S. News & World Report. Hackensack University Medical Center is the only hospital in New Jersey with the #1 adult and children's hospital rankings.

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's best cancer center, as recognized by U.S. News & World Report. This premier cancer center is also the largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. John Theurer Cancer Center is part of Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center.

Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to ensure that patients have access to the highest quality, most individualized cancer care when and where they need it.

The Hackensack Meridian School of Medicine, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its campus in Nutley and Clifton. The Hackensack Meridian Center for Discovery and Innovation (CDI), housed in a fully renovated state-of-the-art facility, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions.

Hackensack MeridianHealthis a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies. To learn more, visitwww.hackensackmeridianhealth.org.

About the Center for Discovery and InnovationThe Center for Discovery and Innovation, a newly established member of Hackensack MeridianHealth, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

For additional information, please visitwww.hmh-cdi.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cdi-director-perlin-named-to-modern-healthcares-class-of-top-25-innovators-301361851.html

SOURCE Hackensack Meridian Health

Original post:
CDI Director Perlin Named to Modern Healthcare's Class of Top 25 Innovators - Markets Insider

Posted in Molecular Genetics | Comments Off on CDI Director Perlin Named to Modern Healthcare’s Class of Top 25 Innovators – Markets Insider

What Is the Most Important Scientific Development of the Last 50 Years? – Gizmodo

Posted: August 31, 2021 at 2:04 am

Illustration: Benjamin Currie/Gizmodo

There are people who argue, persuasively, that Hollywood films are worse than they used to be. Or that novels have turned inward, away from the form-breaking gestures of decades past. In fact, almost anything can be slotted into a narrative of declinethe planet, most obviously, but also (per our former president) toilets and refrigerators. One of the few arenas immune to this criticism is science: I doubt there are very many people nostalgic for the days before the theory of relativity or the invention of penicillin. Over the centuries, science has just kept racking up the wins. But which of these winslimiting ourselves to the last half-centurymattered most? What is the most important scientific development of the last 50 years? For this weeks Giz Asks, we reached out to a number of experts to find out.

Research Assistant, Social Sciences, Humboldt University of Berlin

A bit more than 50 years ago, but I would say the most influential were the related developments of the Journal Impact Factor and the Science Citation Index (precursor of todays Web of Science) by Eugene Garfield and Irving H. Sher between 1955 and 1961.

These developments laid the groundwork for current regimes of governance and evaluation in academia. Their influence on the structure of science as we know it can hardly be overestimated: Today, it is difficult to imagine any funding, hiring, or publication decision that does not draw in some way either directly on the JIF or data from the Web of Science, or at least on some other form of quantitative assessment and/or large-scale literature database. Additionally, the way we engage with academic literature and hence how we learn about and build on research results has also fundamentally been shaped by those databases.

As such, they influence which other scientific developments were made possible in the last 50 years. Some groundbreaking discoveries might have only been possible under this regime of evaluation of the JIF and the SCI, because those projects might not have been funded under a different regimebut also, its possible that we missed out on some amazing developments because they did not (promise to) perform well in terms of quantitative assessment and were discarded early on. Current debates also highlight the perverse and negative effects of quantitative evaluation regimes that place such a premium on publications: goal displacement, gaming of metrics, and increased pressure to publish for early career researchers, to name just a few. So while those two developments are extremely influential, they are neither the only nor necessarily the best possible option for academic governance.

Professor, History of Science, Stanford University, whose research focuses on 20th century science, technology, and medicine

That would surely be the discovery and proof of global warming. Of course, pieces of that puzzle were figured out more than a century ago: John Tyndall in the 1850s, for example, showed that certain gases trap rays from the sun, keeping our atmosphere in the toasty zone. Svante Arrhenius in 1896 then showed that a hypothetical doubling of CO2, one of the main greenhouse gases, would cause a predictable amount of warmingwhich for him, in Sweden, was a good thing.

It wasnt until the late 1950s, however, that we had good measurements of the rate at which carbon was entering our air. A chemist by the name of Charles Keeling set up a monitoring station atop the Mauna Loa volcano in Hawaii, and soon thereafter noticed a steady annual increase of atmospheric CO2. Keelings first measurements showed 315 parts per million and growing, at about 1.3 parts per million per year. Edward Teller, father of the H-bomb, in 1959 warned oil elites about a future of melting ice caps and Manhattan under water, and in 1979 the secret sect of scientists known as the Jasons confirmed the severity of the warming we could expect. A global scientific consensus on the reality of warming was achieved in 1990, when the Intergovernmental Panel on Climate Change produced its first report.

Today we live with atmospheric CO2 in excess of 420 parts per million, a number that is still surging every year. Ice core and sea sediment studies have shown that we now have more carbon in our air than at any time in the last 4 million years: the last time CO2 was this high, most of Florida was underwater and 80-foot sharks with 8-inch teeth roamed the oceans.

Coincident with this proof of warming has been the recognition that the history of the earth is a history of upheaval. Weve learned that every few million years Africa rams up against Europe at the Straits of Gibraltar, causing the Mediterranean to desiccatewhich is why there are canyons under every river feeding that sea. We know that the bursting of great glacial lakes created the Scablands of eastern Washington State, but also the channel that now divides France from Great Britain. We know that the moon was formed when a Mars-sized planet crashed into the earth and that the dinosaurs were killed by an Everest-sized meteor that slammed into the Yucatan some 66 million years ago, pulverizing billions of tons of rock and strewing iridium all over the globe. All of these things have been only recently proven. Science-wise, we are living an era of neo-geocatastrophism.

Two things are different about our current climate crisis, however.

First is the fact that humans are driving the disaster. The burning of fossil fuels is a crime against all life on earth, or at least those parts we care most about. Pine bark beetles now overwinter without freezing, giving rise to yellowed trees of death. Coral reefs dissolve, as the oceans acidify. Biodisasters will multiply as storms rip ever harder, and climate fires burn hotter and for longer. Organisms large and small will migrate to escape the heat, with unknown consequences. The paradox is that all these maladies are entirely preventable: we cannot predict the next gamma-ray burst or solar storm, but we certainly know enough to fix the current climate crisis.

The second novelty is the killer, however. For unlike death-dealing asteroids or gamma rays, there is a cabal of conniving corporations laboring to ensure the continued burning of fossil fuels. Compliant governments are co-conspirators in this crime against the planetalong with think tanks like the American Petroleum Institute and a dozen-odd other bill-to-shill institutes. This makes the climate crisis different from most previous catastrophes or epidemics. It is as if the malaria mosquito had lobbyists in Congress, or Covid had an army of attorneys. Welcome to the Anthropocene, the Pyrocene, the Age of Agnotology!

So forget the past fifty years: the discovery of this slow boil from oil could well become the most important scientific discovery in all of human history. What else even comes close?

G/O Media may get a commission

Professor and Chair, History of Science, The University of Oklahoma

Id say the best candidate is the set of ideas and techniques associated with sequencing genes and mapping genomes.

As with most revolutionary developments in science, the genetic sequencing and mapping revolution wasnt launched by a singular discovery; rather, a cluster of new ideas, tools, and techniques, all related to manipulating and mapping genetic material, emerged around the same time. These new ideas, tools, and techniques supported each other, enabling a cascade of continuing invention and discovery, laying the groundwork for feats such as the mapping of the human genome and the development of the CRISPR technique for genetic manipulation. Probably the most important of these foundational developments were those associated with recombinant DNA (which allow one to experiment with specific fragments of DNA), with PCR (the polymerase chain reaction, used to duplicate sections of DNA precisely, and in quantity), and with gene sequencing (used to determine the sequences of base pairs in a section of DNA, and thus to identify genes and locate them relative to one another). While each of these depended upon earlier ideas and techniques, they all took marked steps forward in the 1970s, laying the foundation for rapid growth in the ability to manipulate genetic material and to map genes within the larger genomes of individual organisms. The Human Genome Project, which officially ran from 1990-2003, invested enormous resources into this enterprise, spurring startling growth in the speed and accuracy of gene sequencing.

The ramifications of this cluster of developments, both intellectual and practical, have been enormous. One the practical side, the use of DNA evidence in criminal investigation (or in exonerating the wrongly convicted), is now routine, and the potential for precise, real-time genomic identification (and surveillance) is being realized at a startling pace. While gene therapies are still in their infancy, the potential they offer is tantalizing, and genomic medicine is growing rapidly. Pharmaceutical companies now request DNA samples from individual experimental subjects in clinical trials in order to correlate drug efficacy with aspects of their genomes. And, perhaps most important of all, the public health aspects of gene sequencing and mapping are stunning: the genome of the SARS-2 Coronavirus that causes Covid-19 was sequenced by the end of February 2020, within weeks of the realization that it could pose a serious public health threat, and whole-genome analysis of virus samples from around the world, over time, have enabled public health experts to map its spread and the emergence of variants in ways that would have been unthinkable even a decade ago. The unique aspects of the virus that make it so infectious were identified with startling speed, and work on an entirely new mode of vaccine development began, leading to the development, testing, and mass production of a new class of vaccines (mRNA vaccines) of remarkable efficacy, in unbelievably short timeless than a year from identification of the virus to approval and wide use. It is hard to overstate how amazing this novel form of vaccine development has been, and how large its potential is for future vaccines.

On the intellectual/cultural side, the collection of techniques for manipulating and mapping genetic material is challenging longstanding ideas about what is natural and about what makes us human. Organic, living things now can be plausibly described as technologies, and thats an unsettling thing. Aspects of our individual biological identities that once were givens are increasingly becoming choices, with implications we are just beginning to see. In addition, these same techniques are being deployed to reconstruct our understanding of evolutionary history, including our own evolution and dispersal across the globe, and perhaps nothing is more significant than changing how we understand ourselves and our history.

Professor, Science and Technology Studies, University College London, who researches the history of modern science and technology

My answer would be PCRPolymerase Chain Reaction. Invented by Kary Mullis at the Cetus Corporation in California in 1985, its as important to modern genetics and molecular biology as the triode and the transistor to modern electronics. Indeed it has the same role: its an amplifier. DNA can be multiplied. Its a DNA photocopier. Without it, especially once automated, much modern genetics would be extremely time-consuming, laborious handcraft, insanely expensive, and many of its applications would not be feasible. It enables sequencing and genetic fingerprinting, and we have it to thank for COVID tests and vaccine development. Plus, you can turn it into a fantastic song by adapting the lyrics to Sleaford Mods TCR. Singalong now: P! C! R! Polymerase! Chain! Reaction!

Read more:
What Is the Most Important Scientific Development of the Last 50 Years? - Gizmodo

Posted in Molecular Genetics | Comments Off on What Is the Most Important Scientific Development of the Last 50 Years? – Gizmodo

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology – OncLive

Posted: August 31, 2021 at 2:02 am

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dosebased radiotherapy dosing in oncology.

Jacob G. Scott, MD, DPhil, associate staff, Departments of Translational Hematology and Oncology Research and Radiation Oncology, Cleveland Clinic, clinical assistant professor, Department of Molecular Medicine, adjunct assistant professor, Department of Physics, Case Western Reserve University School of Medicine, member, Development Therapeutics Program, Case Comprehensive Cancer Center, Case Western Reserve University, discusses the incorporation of genomic-adjusted radiation dose (GARD)based radiotherapy dosing in oncology.

Although it can be difficult to define levels of evidence in biomarker studies based on archival tissue specimens, GARD-based radiotherapy dosing is backed by level 1 evidence and is potentially ready for use in clinical practice, Scott says. However, incorporating a clinical decision support tool will require some relearning of practice standards, which have always been based on empirical evidence from dose-escalation trials, Scott explains.

The tool, which is similar to an oncotype assay, supports the idea that quantifying the biological effect of radiotherapy with GARD is associated with time to first recurrence and overall survival for patients with cancer who undergo radiation treatment. Moreover, GARD-based dosing is predictive of benefit with radiation therapy, Scott concludes.

Visit link:
Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology - OncLive

Posted in Molecular Medicine | Comments Off on Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology – OncLive

Delta is the major variant in the Western Province – J’pura University report – Newsfirst.lk

Posted: August 31, 2021 at 2:02 am

COLOMBO (News 1st): Four mutations of COVID-19 Delta Variant were found in Western Province, researchers at the University of Sri Jayawardenapura said.

University of Sri Jayawardenapura researchers including Prof. Neelika Malavige, Dr. Chandima Jeewandara from the Allergy, Immunology and Cell Biology Unit of the Department of Immunology Molecular and Molecular Medicine released a report confirming the discovery of Delta variant with four mutations within the Western Province itself.

The report states that out of the four mutations, 2 mutations (A701S, R24C) are found only in Sri Lanka and one mutation (A1078S) was present only in Malaysia and Sri Lanka, while the other mutation (A222V) is the common delta variant present in many other countries.

Out of the 94 samples for the research, the areas Colombo (CMC and various areas, Hanwella, Kaduwela), Nuwaraeliya (Bogawantalawa, Dikoya, Lindula), Embilipitiya, Matara (Dickwella, ), Gampaha (Ganemulla, Makola, Ragama, Weyangoda), Kegalle, Point Pedro, Puliyakulam and Vaviniya have been identified as Delta variant infected areas.

Moreover, only 3 samples of the alpha variant [B.1.1.7 (alpha)] have been identified from Anuradhapura, Bohawantalaka and Kandawalai.

Accordingly, the major variant spreading in the Colombo District, the Delta variant, has spread to other Districts of the country as well.

The researchers observed that the frequency of the mutated delta appears to increase over the time, suggesting that it could be more transmissible than the original Delta (delta without these 4 mutations). However more data is required for the researchers to conclude.

While the vast majority of viruses have been sequenced in the Colombo district, sequencing has been carried out from many areas from all over Sri Lanka.

USJ researchers found Four mutant Covid Delta variants with two new Sri Lankan mutations (A701S, R24C) USJ University of Sri Jayewardenepura, Sri Lanka (sjp.ac.lk)

Here is the original post:
Delta is the major variant in the Western Province - J'pura University report - Newsfirst.lk

Posted in Molecular Medicine | Comments Off on Delta is the major variant in the Western Province – J’pura University report – Newsfirst.lk

NIH launches study of extra COVID-19 vaccine dose in people with autoimmune disease – National Institutes of Health

Posted: August 31, 2021 at 2:02 am

News Release

Friday, August 27, 2021

Trial also will test pausing immunosuppressive medication to improve antibody response.

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

Many people who have an autoimmune disease that requires immunosuppressive therapy have had a poor immune response to the authorized and approved COVID-19 vaccines, placing these individuals at high risk for the disease, said NIAID Director Anthony S. Fauci, M.D. We are determined to find ways to elicit a protective immune response to the vaccines in this population. This new study is an important step in that direction.

An estimated 8% of Americans have an autoimmune disease, including a disproportionate number of people in the minority communities most severely impacted by COVID-19. Researchers have reported higher rates of severe COVID-19 and death in people with autoimmune disease than in the general population. It is unclear whether this is attributable to the autoimmune disease, the immunosuppressive medications taken to treat it, or both.

The results of recent studies indicate that giving an extra dose of an authorized COVID-19 vaccine to solid organ transplant recipients, who must take immunosuppressive medications, can improve the immune response to the vaccine in many of these individuals. A NIAID study is underway to investigate this further. The recent findings in solid organ transplant recipients also suggest that an extra dose of a COVID-19 vaccine may help some people with autoimmune disease who take certain immunosuppressive medications. The Food and Drug Administration recently amended the emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow the administration of an additional dose to solid organ transplant recipients and other people who have an equivalent level of immunocompromise.

The new NIAID trial, called COVID19 Booster Vaccine in Autoimmune Disease NonResponders, initially will include people with one of five autoimmune diseases: multiple sclerosis, pemphigus, rheumatoid arthritis, systemic lupus erythematosus or systemic sclerosis. The immunosuppressive therapies commonly taken by people with these diseases have been associated with poor immune responses to vaccines.

The study team will enroll approximately 600 participants ages 18 years and older at 15 to 20 sites nationwide. Participants must have had a negative or suboptimal antibody response to two doses of the Moderna COVID-19 vaccine, two doses of the Pfizer-BioNTech COVID-19 vaccine, or one dose of the Johnson & Johnson COVID-19 vaccine, all received prior to enrollment. Participants also must be taking one of three immunosuppressive therapies: mycophenolate mofetil (MMF) or mycophenolic acid (MPA); methotrexate (MTX); or B cell- depleting drugs.

All participants will receive an extra dose of the same COVID-19 vaccine as they received originally. Then those participants who are taking MMF/MPA or MTX will be assigned at random either to continue taking their immunosuppressive medication without alteration or to pause taking their medication for a short period before and after receiving the extra vaccine dose. The main goal of the study is to determine the proportion of participants who have a significantly better antibody response four weeks after receiving the extra vaccine dose than they did after their original vaccinations.

Study participants will be followed for a total of 13 months. Preliminary results are expected in November 2021.

The COVID19 Booster Vaccine in Autoimmune Disease NonResponders trial is being led by Judith James, M.D., Ph.D., Meggan Mackay, M.D., M.S., Dinesh Khanna, M.B.B.S., M.Sc., and Amit Bar-Or, M.D., F.R.C.P.C. Dr. James is vice president of clinical affairs and program chair of the Arthritis & Clinical Immunology research program at the Oklahoma Medical Research Foundation in Oklahoma City. Dr. Mackay is a professor in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research in Manhasset, New York. Dr. Khanna is the Frederick G.L. Huetwell professor of rheumatology and the director of the scleroderma program in the department of internal medicine at University of Michigan in Ann Arbor. Dr. Bar-Or is the director of the Center for Neuroinflammation and Neurotherapeutics, chief of the multiple sclerosis division, and the Melissa and Paul Anderson President's Distinguished Professor at the University of Pennsylvania in Philadelphia.

Additional information about the COVID19 Booster Vaccine in Autoimmune Disease NonResponders trial, including the locations of study sites, is available in ClinicalTrials.gov under study identifier NCT05000216.

NIAID conducts and supports researchat NIH, throughout the United States, and worldwideto study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing, and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Read the original post:
NIH launches study of extra COVID-19 vaccine dose in people with autoimmune disease - National Institutes of Health

Posted in Molecular Medicine | Comments Off on NIH launches study of extra COVID-19 vaccine dose in people with autoimmune disease – National Institutes of Health

Largest Study of Long COVID Points to an Alarming Prognosis – BioSpace

Posted: August 31, 2021 at 2:02 am

The body of real-world evidencearound COVID-19 continues to build, and a study released Thursday in The Lancet points to concerning long-term effects for hospital survivors at the one-year mark.

The study, which was led by Dr. Bin Cao from the China-Japan Friendship Hospital in Beijing, is a head-to-head comparison of 1,276 people discharged from Jin Yin-Tan Hospital in Wuhan between January and May 2020 and comparable Wuhan residents who were not infected with COVID-19. In what is the largest paper of its kind yet to be published, the former patients were assessed at both six and 12 months following the onset of their first symptoms.

Common long-term effects suffered by COVID-19 survivors include fatigue, muscle weakness, sleep disturbances, changes in taste and smell, dizziness, headache and shortness of breath. At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year. In all, the former patients self-reported experiencing a lower quality of life than their counterparts, and the most common maladies were fatigue and muscle weakness.

Reflective of the enigma that is COVID-19, the number of patients reporting breathing problems actually increased between the six and 12-month check-ins from 26% to 30%, while the percentage of people who felt anxious or depressed rose from 23% at six months to 30% at one year. Both mental and physical health challenges were especially prevalent among those who had experienced the most serious disease.

That people would still be in a rehabilitation period after 12 months is outside of the norm for David Putrino, director of rehabilitation innovation at Mount Sinai Health Systems in New York. Putrino told TIME that this is not an example of a glass-half-full story.

After most hospital stays, including for, say, walking pneumonia, I would not be expecting people at 12 months to still be reporting symptoms to me, said Putrino, who oversees the networks Long COVID rehabilitation program.

According to Putrino, being fortunate enough to escape hospitalization may not guarantee a full immediate recovery.

This virus doesnt end once you get discharged from the hospital or once you get over the initial acute symptoms, he said, referencing smaller studies showing that symptoms may linger in around 20% of these patients.

These studies could spell bad news for a lot of survivors. According to a collection of four international studies published in late July, there are more than 200 possible Long COVID symptoms. In one paper, researchers assessed responses from 3,762 patients from 56 countries with either confirmed or suspected COVID-19 and found an average of 56 reported symptoms across 9 different organ systems. More than 91% of these patients required at least 35 weeks to recover. The most commonly reported symptoms after six months were fatigue, post-exertional malaise, and cognitive disfunction.

It appears that even vaccination is not a complete get out of jail free card in every case when it comes to preventing Long COVID. In an Israeli study of 1,497 vaccinated health care workers, 39 became infected regardless, and 7 of those individuals experienced symptoms that lasted at least six weeks.

"We had hoped that when you get vaccinated and even if you did have a breakthrough infection you would have enough of an immune response that would block this protracted symptom complex now known as long COVID, said Dr. Eric Topol, a professor of molecular medicine at Scripps Research. This study is the really first to give us an indicator that there's some long-haulers among that small group of people that had breakthrough infections.

Read the original:
Largest Study of Long COVID Points to an Alarming Prognosis - BioSpace

Posted in Molecular Medicine | Comments Off on Largest Study of Long COVID Points to an Alarming Prognosis – BioSpace

Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing – Business Wire

Posted: August 31, 2021 at 2:02 am

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genome Medical, the leading nationwide genomic care delivery company, today announced that it will acquire GeneMatters, a telehealth genetic counseling and software solutions company. Simultaneously, the company announced the closing of a $60 million Series C financing to accelerate commercial traction and advance its mission of transforming health care for all through genomic medicine. These strategic initiatives solidify its position as the preeminent technology-enabled provider of genetic health services and genomic insights.

The addition of GeneMatters, along with our Series C financing, propels us into the next phase of commercial growth and enables us to realize the genome-driven personalization of health, said Lisa Alderson, co-founder and CEO of Genome Medical. The genomic medicine industry is primed with testing capabilities and novel therapeutics; now is clearly the moment for Genome Medical to deliver expanded availability of genomic medicine for patients and providers.

Genome Medical will use the financing proceeds to expand its team and further enhance the development of its configurable technology solutions to provide innovative and efficient genomic medicine programs. The company will continue to build out its full suite of physician services, test ordering capabilities and guidelines-based care plans to ensure comprehensive, seamless care for patients.

The Series C round was led by Casdin Capital, a committed and leading long-term investor in life sciences and genomics, and was joined by new investors GV (formerly Google Ventures) and Amgen Ventures. Existing investors also participated, including Perceptive Advisors, Canaan Partners, Kaiser Permanente Ventures, Illumina Ventures, LRVHealth, Echo Health Ventures, Revelation Partners, HealthInvest Equity Partners, Avestria Ventures, Flywheel Ventures, Dreamers Fund and Blue Ivy Ventures.

In connection with the financing, the Genome Medical Board of Directors will be joined by Eli Casdin, founder and chief investment officer at Casdin Capital; Shaun Rodriguez, director of life science research at Casdin Capital; and Jill Davies, co-founder and president of GeneMatters. Anthony Philippakis, M.D., Ph.D., venture partner at GV, will join the board as an observer.

We feel fortunate to have been in the unique position to facilitate this strategic combination of two strong genomic health providers and Casdin portfolio companies, Eli Casdin said. We have been an early and active investor in the development of genetic testing capabilities broadly. The breadth and scale of Genome Medical and GeneMatters together produce the clear leader in digital health for genomics. It is also a terrific example of how one + one can equal more than two!

Together, Genome Medical and GeneMatters represent expanded technology solutions and clinical expertise to better meet the growing need for genomic medicine across health and wellness. GeneMatters will operate as a wholly owned subsidiary of Genome Medical Holding Company, with a focus on expanding the delivery of genetic services to community health systems and other partners.

The mission of GeneMatters from day one has been to increase patient access to genetic services and to support patient decision-making, said GeneMatters Davies. Joining the Genome Medical family allows for expanded capabilities, broader reach and ultimately more patients and providers being served. We are thrilled to be joining forces with this talented team that shares our mission, vision and passion for patient care.

By combining innovative, technology-enabled solutions with the virtual delivery of industry-leading clinical expertise, Genome Medical is accelerating the adoption of genetic services and genomic medicine for health care systems, large-scale research studies, health plans, employers, providers and molecular diagnostic testing laboratories. Learn more about Genome Medicals comprehensive services, including its Genome Care DeliveryTM platform and precision insights for population genomics.

About Genome Medical

Genome Medical, the leading genomic care delivery company, is personalizing health care for all through on-demand access to genetic insights and genomic medicine. We operate as an independent virtual medical practice, powered by a digital health technology platform. By partnering with health systems, providers, health plans, employers, labs and biopharma, we expand the reach and impact of precision medicine. We provide clinical assessments and tools, test recommendations and ordering, and personalized care plans to deliver optimal patient care and improve health outcomes. The company, which is headquartered in South San Francisco, was recently honored as The Best Digital Health Company to Work For by Rock Health, Fenwick & West and Goldman Sachs in their Top 50 in Digital Health awards. To learn more, visit genomemedical.com and follow @GenomeMed.

About GeneMatters

GeneMatters is a leading provider of telehealth genetic counseling and software solutions to increase access to genetic services. We deliver customizable solutions to hospitals, health networks, genetic testing labs and biopharmaceutical organizations to extend the capacity of existing genetic counseling teams, support new programs and increase patient engagement with genetic services. Our genetic expertise spans oncology, reproductive, cardiovascular and rare diseases. Founded in 2016 by Jill Davies, a genetic counselor, with a mission to increase patient access, we are committed to outstanding service delivery, unwavering quality standards, high patient satisfaction and technology to simplify care. To learn more, visit gene-matters.com and follow @GeneMatters on Twitter Linkedin

More:
Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing - Business Wire

Posted in Molecular Medicine | Comments Off on Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing – Business Wire

Page 659«..1020..658659660661..670680..»